The founding team has spent the past 20 years and over $11MM in grant funding to conduct basic and translational research leading to the discovery of a novel biomarker to detect CKD in a single assessment. During this time, PrognostX Health is proud to have been shaped by the Larta Institute’s NIH Commercialization Acceleration Program, Eva Garland Consulting’s NIH SBIR Acceleration Program, LaunchBlue’s Technology-focused UAccel Commercialization Program, and the Beckman Coulter Foundation’s Concept to Clinical: Commercializing Innovation (C3i) Accelerator Program.
This non-filtration dependent biomarker test offers physicians a new and complementary perspective to renal health. In a 384 patient study, our novel biomarker identified CKD Stages 3a, 3b, and 4 at a 97% accuracy, with an ROC analysis demonstrating 98% sensitivity, 97% specificity, 94% PPV, and 99% NPV (AUC = 0.982) on a single assessment.